HomeGeneticsConditionAbetalipoproteinemia
Back to Condition
Abetalipoproteinemia
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Abetalipoproteinemia

Abetalipoproteinemia is a rare inherited disorder that impairs the normal absorption of fats and fat-soluble vitamins (A, E, and K) from the diet, leading to a range of signs and symptoms primarily affecting the eyes, nervous system, and blood, often appearing in infancy.

Overview

Abetalipoproteinemia is an inherited disorder that impairs the normal absorption of fats and certain vitamins from the diet. Many of the signs and symptoms of abetalipoproteinemia result from a severe shortage (deficiency) of fat-soluble vitamins (vitamins A, E, and K). The signs and symptoms of this condition primarily affect eyes, nervous system, and blood.

The first signs and symptoms of abetalipoproteinemia appear in infancy. They often include:

  • Failure to gain weight and grow at the expected rate (failure to thrive)
  • Diarrhea
  • Fatty, foul-smelling stools (steatorrhea)

As an individual with this condition ages, additional signs and symptoms include disturbances in nerve function that may lead to:

  • Poor muscle coordination and difficulty with balance and movement (ataxia)
  • Loss of certain reflexes
  • Impaired speech (dysarthria)
  • Tremors or other involuntary movements (motor tics)
  • Loss of sensation in the extremities (peripheral neuropathy)
  • Muscle weakness

The muscle problems can disrupt skeletal development, leading to:

  • An abnormally curved lower back
  • A rounded upper back that also curves to the side
  • High-arched feet
  • An inward- and upward-turning foot

Individuals with this condition may also develop an eye disorder called retinitis pigmentosa, in which breakdown of the light-sensitive layer at the back of the eye can cause vision loss. In individuals with abetalipoproteinemia, the retinitis pigmentosa can result in complete vision loss. People with abetalipoproteinemia may also have other eye problems, including:

  • Involuntary eye movements (nystagmus)
  • Eyes that do not look in the same direction (strabismus)
  • Weakness of the external muscles of the eye (ophthalmoplegia)

Individuals with abetalipoproteinemia usually have a low number of red blood cells with abnormally star-shaped red blood cells (acanthocytosis) and have difficulty forming blood clots, which can cause abnormal bleeding. In some cases, a condition called fatty liver develops, which can cause liver damage.

Frequency

Abetalipoproteinemia is a rare disorder. More than 100 cases have been described worldwide.

Causes & Risk Factors

Abetalipoproteinemia is caused by mutations in the MTTP gene, which provides instructions for making a protein called microsomal triglyceride transfer protein. This protein is essential for creating molecules called beta-lipoproteins in the and . Beta-lipoproteins fats, cholesterol, and fat-soluble vitamins from the intestine to the bloodstream so these nutrients can be taken up by tissues throughout the body. Sufficient levels of fats, cholesterol, and vitamins are necessary for normal growth, development, and maintenance of the body's cells and tissues.

Most MTTP gene mutations lead to the production of microsomal triglyceride transfer protein with reduced or absent function and unable to help in the formation of beta-lipoproteins. A lack of beta-lipoproteins causes severely reduced absorption (malabsorption) of dietary fats and fat-soluble vitamins from into the bloodstream. These nutritional deficiencies lead to health problems in people with abetalipoproteinemia.

Genes Associated with Abetalipoproteinemia

  • MTTP

Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names

  • Abetalipoproteinaemia
  • Abetalipoproteinemia neuropathy
  • ABL
  • Acanthocytosis
  • Apolipoprotein B deficiency
  • Bassen-Kornzweig disease
  • Bassen-Kornzweig syndrome
  • Betalipoprotein deficiency disease
  • Congenital betalipoprotein deficiency syndrome
  • Microsomal triglyceride transfer protein deficiency disease
  • MTP deficiency

Frequently Asked Questions

betalipoproteinemia is inherited in an autosomal recessive pattern. This means that an individual must inherit two copies of the mutated gene (one from each parent) to develop the condition. Parents who are carriers (have one mutated copy) typically do not show symptoms but have a 25% chance with each pregnancy of having a child with abetalipoproteinemia. Genetic counseling is recommended for affected individuals and their families to understand inheritance risks and discuss family planning options, including prenatal diagnosis.
Long-term complications primarily affect the nervous system and eyes. Progressive neurological issues like ataxia, muscle weakness, and peripheral neuropathy require ongoing physical therapy, occupational therapy, and close monitoring by a neurologist. Retinitis pigmentosa, which can lead to severe vision loss, is monitored by an ophthalmologist, and high-dose vitamin A supplementation is crucial to try and preserve vision. Regular follow-up with a multidisciplinary team is essential to manage symptoms and adjust treatment.
Diagnosis typically involves a combination of clinical evaluation, blood tests, and genetic testing. Blood tests will show very low or absent levels of beta-lipoproteins, cholesterol, and triglycerides, along with deficiencies in fat-soluble vitamins (A, E, K). A blood smear may reveal characteristic spiky red blood cells called acanthocytes. Genetic testing confirms the diagnosis by identifying mutations in the MTTP gene.
The primary treatment involves a strict low-fat diet to reduce gastrointestinal symptoms and high-dose supplementation of fat-soluble vitamins (A, E, K, and often D) to prevent or slow the progression of neurological and eye complications. Vitamin E is particularly important for neurological health and is given in very high doses. Medium-chain triglycerides (MCTs) may be used as a fat source because they are absorbed without the need for beta-lipoproteins.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab